Join
Live feed
·
PRReleasevia Quantisnow
Quince Therapeutics Inc. logo

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

ByQuantisnow·Wall Street's wire, on your screen.
QNCX· Quince Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track QNCX (Quince Therapeutics Inc.) and more on Quantisnow.